Search
Adaptimmune Therapeutics PLC
ADAPAdd to Watchlist
0.055USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
10.34MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
0.00%
1 Month
0.00%
6 Months
0.00%
Year to Date
0.00%
1 Year
-78.04%
Key Figures
--Open
0.000High
0.00Volume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
3.19%Turnover Ratio
0.055Prev. Close
0.000Low
0.00Turnover
LossP/E Static
-1.23P/B
0.00%Div Yield TTM
-75.06%ROA
0.86052wk High
0.34Volume Ratio
-70.81MNet Profit
1.59BShares
-0.6642EPS TTM
2.38Beta
-1341.10%ROE
0.04052wk Low
27.05%Amplitude
81.71%Gross Margin
10.34MMarket Cap
-5.10Reward/Risk
9.86%Risk Rate
TradingKey Stock Score
No stock score available due to insufficient data.
Adaptimmune Therapeutics PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Adaptimmune Therapeutics PLC Info
Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.
Ticker SymbolADAP
CompanyAdaptimmune Therapeutics PLC
CEORawcliffe (Adrian George)
Websitehttps://www.adaptimmune.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Adaptimmune Therapeutics PLC (ADAP)?
The current price of Adaptimmune Therapeutics PLC (ADAP) is 0.05.
What is the symbol of Adaptimmune Therapeutics PLC?
The ticker symbol of Adaptimmune Therapeutics PLC is ADAP.
What is the 52-week high of Adaptimmune Therapeutics PLC?
The 52-week high of Adaptimmune Therapeutics PLC is 0.86.
What is the 52-week low of Adaptimmune Therapeutics PLC?
The 52-week low of Adaptimmune Therapeutics PLC is 0.04.
What is the market capitalization of Adaptimmune Therapeutics PLC?
The market capitalization of Adaptimmune Therapeutics PLC is 10.34M.
What is the Earnings Per Share (EPS TTM) of Adaptimmune Therapeutics PLC (ADAP)?
The Earnings Per Share (EPS TTM) of Adaptimmune Therapeutics PLC (ADAP) is -0.28.